Home » Stocks » Chembio Diagnostics

Chembio Diagnostics, Inc. (CEMI)

Stock Price: $4.91 USD -0.04 (-0.81%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed
Pre-market: $4.97 +0.06 (1.22%) Oct 21, 4:39 AM

Stock Price Chart

Key Info

Market Cap 98.99M
Revenue (ttm) 28.54M
Net Income (ttm) -20.52M
Shares Out 20.16M
EPS (ttm) -1.17
PE Ratio n/a
Forward PE 6.72
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $4.91
Previous Close $4.95
Change ($) -0.04
Change (%) -0.81%
Day's Open 4.94
Day's Range 4.84 - 5.07
Day's Volume 1,415,151
52-Week Range 2.25 - 15.89

More Stats

Market Cap 98.99M
Enterprise Value 88.15M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 20.16M
Float 17.34M
EPS (basic) -1.16
EPS (diluted) -1.17
FCF / Share -0.75
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.49M
Short Ratio 2.26
Short % of Float 25.91%
Beta 2.14
PE Ratio n/a
Forward PE 6.72
P/FCF Ratio n/a
PS Ratio 3.47
PB Ratio 2.51
Revenue 28.54M
Operating Income -18.62M
Net Income -20.52M
Free Cash Flow -14.08M
Net Cash 10.84M
Net Cash / Share 0.54
Gross Margin 12.61%
Operating Margin -65.23%
Profit Margin -71.90%
FCF Margin -49.32%
ROA -17.83%
ROE -61.54%
ROIC -40.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 0
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$5.00*
(1.83% upside)
Low
5.00
Current: $4.91
High
5.00
Target: 5.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue34.4634.5824.0217.8724.2627.6529.5525.6119.3916.70
Revenue Growth-0.34%44%34.4%-26.33%-12.26%-6.44%15.38%32.09%16.06%-
Gross Profit12.0711.9811.098.4510.4910.8112.3010.799.398.10
Operating Income-13.33-7.98-6.48-7.57-3.55-1.551.001.451.092.57
Net Income-13.68-7.87-6.37-13.35-2.40-1.140.530.946.212.51
Shares Outstanding16.9514.4312.3010.629.639.538.997.997.877.76
Earnings Per Share-0.81-0.54-0.52-1.26-0.25-0.120.060.110.730.32
EPS Growth-------45.45%-84.93%128.13%-
Operating Cash Flow-9.06-11.78-5.03-6.701.79-3.822.280.762.271.02
Capital Expenditures-3.50-1.47-1.03-0.12-0.48-1.45-0.89-0.87-0.73-0.18
Free Cash Flow-12.56-13.25-6.06-6.821.31-5.271.39-0.111.540.83
Cash & Equivalents18.2712.523.7910.555.384.619.652.953.012.14
Total Debt25.580.380.10----0.130.200.28
Net Cash / Debt-7.3012.153.6910.555.384.619.652.822.811.86
Assets55.7340.9116.6220.5820.8225.0124.4917.3415.499.09
Liabilities31.697.583.543.413.155.294.313.462.993.28
Book Value24.0433.3313.0817.1717.6619.7220.1813.8712.495.81
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Chembio Diagnostics, Inc.
Country United States
Employees 324
CEO Richard L. Eberly

Stock Information

Ticker Symbol CEMI
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: CEMI
IPO Date October 18, 2000

Description

Chembio Diagnostics, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.